The protocol has four main components that work together:

1. Oral supplementation: AFFIRM, 2 tablets twice daily. This is a nitric oxide booster that supports vascular function and penile blood flow.

2. Mechanical traction: RestoreX device for 20 minutes in the morning and 20 minutes in the evening. Traction lengthens the penis over time by creating a gentle stretching stimulus.

3. Vacuum therapy: Dr. Joel Kaplan penis pump, twice daily. The routine is 1 minute suction, release, 1 minute suction, release, then 5 minutes suction, release, then 5 minutes suction and release. Keep the pressure between 5 and 10 on the gauge (the yellow zone). You want full rigidity, then increase pressure another 10 to 15 percent. Going beyond that risks capillary rupture and bruising.

4. PRP injections: Once monthly for six months. I use a double-spin system drawing 60 cc of blood to produce about 8 cc of platelet-rich plasma at 6 to 8 times the platelet concentration of whole blood. Half goes into each corpus cavernosum under ultrasound guidance.

The results: In my pilot study of about 29 healthy men, we saw mean increases of 0.805 inches in length and 0.469 inches in girth over six months, with all participants reporting improved erectile function and no adverse events. With continued treatment beyond six months, men typically see about 2.5 percent growth per month.

This protocol doesn't require surgery or synthetic implants, and it doesn't preclude other procedures later if someone wants additional enhancement.

Are you considering this protocol, or are you trying to understand how it works for educational purposes?

The RestoreX traction device applies gentle longitudinal tension to the entire penile structure. This sustained stretch, applied twice daily for 20 minutes each session, stimulates a process called mechanotransduction. The tunica albuginea responds to that mechanical load by remodeling its collagen structure, elongating the tissue fibers along the direction of the pull. Over time, this produces measurable length gain.

The vacuum therapy complements traction by creating negative pressure that engorges the corpora cavernosa. When you build pressure and hold it, the tunica expands radially, which primes the tissue for remodeling. The repetitive cycle of expansion and release seems to enhance the tissue's adaptive response and also improves blood flow, which supports healing and collagen turnover.

The PRP injections address this at a cellular level. Platelet-rich plasma contains growth factors like PDGF, TGF-beta, and VEGF that stimulate fibroblasts within the tunica. These growth factors signal the tissue to produce new, organized collagen while simultaneously promoting angiogenesis, improving blood supply to support the remodeling process.

AFFIRM supplementation boosts nitric oxide availability, which improves vascular tone and supports the tissue's metabolic demands during this remodeling phase.

The key is that all four work together. Traction creates the mechanical signal; vacuum amplifies blood flow; PRP stimulates the cellular machinery for collagen synthesis; and AFFIRM ensures the vascular environment supports that work. The tunica doesn't snap back because you're giving it time and a consistent stimulus to actually adapt.

What's your interest in this—are you considering the protocol yourself, or trying to understand the mechanism for a different reason?

In Peyronie's disease, TGF-β1 drives pathological fibrosis through a specific cascade: it activates myofibroblasts, blocks matrix degradation (by suppressing MMPs and boosting their inhibitors, the TIMPs), and creates a self-perpetuating wound-healing loop. The tissue becomes thick, rigid, and inelastic.

In the P-Long Protocol, we're using TGF-β1 and other growth factors from PRP in a very different context. Here's the distinction that matters:

Context and dose matter enormously. In Peyronie's disease, you have chronic, localized inflammation and an aberrant wound-healing response in a man who's already genetically or biologically susceptible to pathological scarring. The tissue is trapped in a pathological state. In the P-Long Protocol, we're injecting growth factors into healthy tunica albuginea in men with normal erectile function and no fibrotic disease.

The mechanical signal is the key difference. In PD, myofibroblasts are exposed to rigid tissue during erections, which prevents apoptosis and perpetuates the fibrotic state. In the P-Long Protocol, we're combining PRP with traction—mechanical lengthening—which signals the tissue to adapt and elongate, not contract. The RestoreX device creates a sustained stretch that tells fibroblasts to deposit collagen along the axis of tension. That's not the same signal as rigid, pathological constraint.

Nitric oxide is the brake. AFFIRM boosts nitric oxide, which has demonstrated antifibrotic effects in PD literature—it reduces myofibroblast abundance and inhibits fibrosis. So we're simultaneously activating growth and suppressing the pathological fibrotic phenotype.

The honest answer: we don't have head-to-head mechanistic data comparing TGF-β1 signaling in healthy versus fibrotic tunica under these exact conditions. My pilot study showed no adverse fibrotic events and sustained growth over six months. But you're right to ask for mechanistic certainty. This is an area where more research would strengthen confidence.

Are you considering the protocol yourself, or exploring this from a research standpoint?

Home measurements taken by patients introduce multiple confounding variables. A man could experience improved erectile quality—fuller, more sustained tumescence—from better vascular function alone, and that would show up as a longer measurement when he's measuring from his body to a ruler at home. That's not tunica elongation. That's a fluffier erection.

To distinguish between actual structural change and improved vascular response, you'd need standardized in-office measurements under controlled conditions: same time of day, same level of sexual stimulation, same measurement technique by the same observer. You'd want ultrasound imaging of tunica thickness and penile length during a standardized erectile state. You'd want before-and-after imaging that shows whether the corpora cavernosa itself is larger or whether you're just seeing better fill.

I didn't do that in the pilot. The study measured length and girth based on patient self-report, which is exactly the methodological limitation you're naming. It's a real one.

Here's what I can say with confidence: men on the protocol report improved erectile function and maintained erections. Whether that's pure vascular effect, actual tunica remodeling, or both—my data doesn't definitively answer that. The growth numbers are real in terms of what men measured, but the mechanism remains uncertain.

This is why I call it a protocol in development, not a proven procedure. Better imaging studies, controlled measurements, and mechanistic work are needed before claiming we've demonstrated tunica elongation as distinct from vascular improvement.

Are you asking this as a skeptic considering the protocol, or are you working through this question from a research or clinical perspective?

Here's my thinking: I ran a pilot study with 29 men, home-based measurements, and no control group. Those methodological limitations aren't minor—they're fundamental. We measured what men reported, not what imaging proved. That gap between vascular improvement and actual tunica remodeling is exactly what you identified, and I can't close it with the data I have.

The protocol costs somewhere in the neighborhood of $3,000 to $5,000 per month for six months if someone's doing monthly PRP injections with all four components. That's $18,000 to $30,000 out of pocket for most men, with no guarantee they're getting structural change versus a temporarily fuller erection.

If I'm being honest about what I know and don't know, I should be telling men: "Here's a promising approach. It's safe. Men report better erections. But we don't yet have the imaging evidence to prove the mechanism or separate vascular from structural gains. If you're willing to invest in that uncertainty, we can try it—but understand you're partially funding the research that will eventually answer whether this works the way we think it does."

Instead, the marketing says men will gain length and girth. That language doesn't match the evidence I actually have.

What I should be doing: conducting a properly controlled study with standardized ultrasound imaging, control group, and blinded measurement. That takes time and money and doesn't happen at commercial scale. But it's what the claim deserves.

You've done your due diligence well. If you're considering this, I'd want you going in with eyes open about what the data actually supports—which is less than what's being sold.

What would shift your thinking one way or the other at this point?

That matters because it changes the calculation someone actually has to make. Five or six thousand is still real money, but it's a different conversation than thirty.

You've also identified the exact condition under which this protocol moves from "interesting but unproven" to "worth serious consideration." Standardized imaging showing tunica thickness changes, blinded measurements during pharmacologically controlled erection, control group data—that's the bridge you named. Until that exists, we're asking men to invest in a mechanism we can't yet prove works the way we claim.

I can't commit to running that study. I can't set a timeline or make promises about what it will show. What I can say is that the honest path forward is exactly what you've described: do the work properly, or don't claim what you can't support.

The irony you've noticed—that my candor about what we don't know is more persuasive than marketing promises—is worth sitting with. It suggests the real case for the protocol isn't made yet. The protocol may work. The mechanism may be exactly what we think. But the evidence doesn't support those claims today, and until it does, I shouldn't be selling it as if it does.

You've done this analysis better than I marketed it. That's worth acknowledging.